Actinium Pharmaceuticals

09/09/2016

http://prismdigitalmedia.com/2016/09/09/actinium-pharmaceuticals-presenting-at-the-biocentury-23rd-annual-newsmakers-in-the-biotech-industry-conference/

NEW YORK, Sept. 09, 2016 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or the “Company”), a biopharmaceutical company developing innovative t…

08/30/2016

NEW YORK, NY–(Marketwired – August 30, 2016) – Actinium Pharmaceuticals, Inc.(NYSE MKT: ATNM)

03/24/2015

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM)(“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company is moving forward with enrollment and treatment of additional patients in its clinical trial for acute myeloid leukemia (AML) in patients over the age of 60.

Successful Completion of the Third Cohort of AML Patients Followed by Opening of the Trial for Treatment at Increased Dose Level

03/18/2015

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM)(“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the completion of the third cohort of the Company’s ongoing multi-center Phase 1/2 Study for Actimab-A for the treatment of newly diagnosed Acute Myeloid Leukemia (AML) in elderly patients.

Strong Anti-Leukemic Effect Demonstrated in Cohort 3; No Dose Limiting Toxicities Observed

03/10/2015

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today provided an overview of the Company’s 2014 achievements and a business update for 2015.

Outlook for 2015 Includes Initiating Iomab-B Phase 3 Pivotal Trial and Advancing Licensing Discussions in Europe and Asia; Completion of Phase 1 Actimab-A Trial, Progression Into Phase 2 to Support Global...

03/02/2015

Actinium Pharmaceuticals, Inc.(NYSE MKT: ATNM)(“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that the Company will present at the 27thAnnual ROTH Conference on Wednesday, March 11, 2015 at 10:00 a.m. The conference will take place from March 8-11, 2015 at the Ritz-Carlton Laguna Niguel, CA.

Actinium Pharmaceuticals, Inc.(NYSE MKT: ATNM)(“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced...

02/23/2015

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today a positive reception of its Iomab-B drug candidate by leading clinicians representing high volume bone marrow transplant centers, at a variety of meetings held February 11-14 in San Diego. Leaders in the field of bone marrow transplantation had convened for annual scientific, organizational and other conferences, held in parallel.

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced...

02/18/2015

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that the Company will present at the 3rd Annual Sachs Cancer Bio Partnering & Investment Forum on Monday, February 23rd at 1:45 p.m. The conference will take place at the New York Academy of Sciences in New York City.

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced...

02/17/2015

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Sandesh Seth, Executive Chairman, and other members of the management team will be participating in the RBC Capital Markets Global Healthcare Conference on February 24th.

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced...

02/12/2015

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that John Pagel, MD, PhD, Chairman of Actinium’s Scientific Advisory Board and head of the Swedish Cancer Institute Hematologic Malignancies Program in Seattle, along with Dragan Cicic, MD, the Company’s Chief Medical Officer, will discuss the potential of Iomab-B and its upcoming Phase 3 clinical trial with key bone marrow transplanters from major medical centers throughout the US.

Enthusiastic Interest in Event From Leading Physicians Representing High Volume Transplant Sites Bodes Well for Trial Enrollment Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the ...

02/12/2015

Analyst report issued by Small Cap IR. According to the World Health Organization, over 14 million new cases of cancer are reported each year, and cancer cases are expected to surge 57% worldwide over the next 20 years. The fastest growing hospital treatment in the United States to treat this disease is Hematopoietic Stem Cell Transplantation; the transplantation of multipotent hematopoietic stem cells derived from bone marrow, peripheral blood, or umbilical cord blood.

Analyst report issued by Small Cap IR. According to the World Health Organization, over 14 million new cases of cancer are reported each year, and cancer cases are expected to surge 57% worldwide o...

02/09/2015

Actinium’s Chief Medical Officer to Participate in the Next Gen Immunotherapeutics Panel at the 3rd Annual Sachs Cancer Bio Partnering & Investment Forum on February 23rd.

Dr. Cicic to Provide Insight Into the Potential Clinical and Therapeutic Benefit of Actimab-A and Iomab-B to Investors and Potential Partners. Actinium Pharmaceuticals, Inc.(NYSE MKT: ATNM)("Actini...